Question to Daniel if I may. Perhaps for the next presentation if the answer will take too long here.
I am interested in your thoughts re Bisantrene vs liposomal Doxorubicin. As I understand it they both have marked reduced cardio toxicity compared to standard and are both well advanced in the clinic. I would value your thoughts as to why Bisantrene may be expected to be better and why oncologists would swap one for the other on a new trial design.
thanks
General Comments / Chat, page-86
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.005(0.34%) |
Mkt cap ! $242.5M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.50 | $1.43 | $62.91K | 43.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 591 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.46 |
Change
-0.005 ( 0.23 %) |
||||
| Open | High | Low | Volume | ||
| $1.44 | $1.49 | $1.43 | 9034 | ||
| Last updated 13.08pm 24/05/2024 ? | |||||
| RAC (ASX) Chart |